

GenCore version 5.1.3  
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: January 9, 2003, 12:23:23 ; Search time 35 Seconds  
(without alignments)  
49.493 Million cell updates/sec

Title: US-09-632-429-4  
Perfect score: 89  
Sequence: 1 WEVLCWTWETCR 13

Scoring table: BLOSUM62  
Gapop 10.0 , Gapext 0.5

Searched: 908470 seqs, 133250620 residues

Total number of hits satisfying chosen parameters: 908470

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database : A\_Geneseq\_101002.\*

- 1: /SIDS2/gcgdata/geneseq/geneseq-emb1/AA1980.DAT.\*
- 2: /SIDS2/gcgdata/geneseq/geneseq-emb1/AA1981.DAT.\*
- 3: /SIDS2/gcgdata/geneseq/geneseq-emb1/AA1982.DAT.\*
- 4: /SIDS2/gcgdata/geneseq/geneseq-emb1/AA1983.DAT.\*
- 5: /SIDS2/gcgdata/geneseq/geneseq-emb1/AA1984.DAT.\*
- 6: /SIDS2/gcgdata/geneseq/geneseq-emb1/AA1985.DAT.\*
- 7: /SIDS2/gcgdata/geneseq/geneseq-emb1/AA1986.DAT.\*
- 8: /SIDS2/gcgdata/geneseq/geneseq-emb1/AA1987.DAT.\*
- 9: /SIDS2/gcgdata/geneseq/geneseq-emb1/AA1988.DAT.\*
- 10: /SIDS2/gcgdata/geneseq/geneseq-emb1/AA1989.DAT.\*
- 11: /SIDS2/gcgdata/geneseq/geneseq-emb1/AA1990.DAT.\*
- 12: /SIDS2/gcgdata/geneseq/geneseq-emb1/AA1991.DAT.\*
- 13: /SIDS2/gcgdata/geneseq/geneseq-emb1/AA1992.DAT.\*
- 14: /SIDS2/gcgdata/geneseq/geneseq-emb1/AA1993.DAT.\*
- 15: /SIDS2/gcgdata/geneseq/geneseq-emb1/AA1994.DAT.\*
- 16: /SIDS2/gcgdata/geneseq/geneseq-emb1/AA1995.DAT.\*
- 17: /SIDS2/gcgdata/geneseq/geneseq-emb1/AA1996.DAT.\*
- 18: /SIDS2/gcgdata/geneseq/geneseq-emb1/AA1997.DAT.\*
- 19: /SIDS2/gcgdata/geneseq/geneseq-emb1/AA1998.DAT.\*
- 20: /SIDS2/gcgdata/geneseq/geneseq-emb1/AA1999.DAT.\*
- 21: /SIDS2/gcgdata/geneseq/geneseq-emb1/AA2000.DAT.\*
- 22: /SIDS2/gcgdata/geneseq/geneseq-emb1/AA2001.DAT.\*
- 23: /SIDS2/gcgdata/geneseq/geneseq-emb1/AA2002.DAT.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	89	100.0	13	22 AAB90146	Factor VIIa (FVIIa
2	89	100.0	15	22 AAB90165	Factor VIIa (FVIIa
3	89	100.0	16	22 AAB90159	Factor VIIa (FVIIa
4	89	100.0	18	22 AAB90160	Factor VIIa (FVIIa
5	89	100.0	22	22 AAB90199	Factor VIIa (FVIIa
6	89	100.0	24	22 AAB90161	Factor VIIa (FVIIa
7	89	100.0	24	22 AAB90168	Factor VIIa (FVIIa
8	89	100.0	24	22 AAB90169	Factor VIIa (FVIIa
9	89	100.0	24	22 AAB90181	Factor VIIa (FVIIa
10	89	100.0	24	22 AAB90182	Factor VIIa (FVIIa

11	89	100.0	24	22 AAB90183	Factor VIIa (FVIIa
12	88	98.9	24	22 AAB90184	Factor VIIa (FVIIa
13	87	97.8	24	22 AAB90185	Factor VIIa (FVIIa
14	87	97.8	24	22 AAB90186	Factor VIIa (FVIIa
15	86	96.6	13	22 AAB90147	Factor VIIa (FVIIa
16	86	96.6	24	22 AAB90187	Factor VIIa (FVIIa
17	86	96.6	24	22 AAB90194	Factor VIIa (FVIIa
18	86	96.6	24	22 AAB90195	Factor VIIa (FVIIa
19	85	95.5	24	22 AAB90172	Factor VIIa (FVIIa
20	84	94.4	24	22 AAB90173	Factor VIIa (FVIIa
21	84	94.4	24	22 AAB90175	Factor VIIa (FVIIa
22	84	94.4	24	22 AAB90178	Factor VIIa (FVIIa
23	84	94.4	24	22 AAB90180	Factor VIIa (FVIIa
24	84	94.4	24	22 AAB90193	Factor VIIa (FVIIa
25	84	94.4	24	22 AAB90196	Factor VIIa (FVIIa
26	84	94.4	24	22 AAB90197	Factor VIIa (FVIIa
27	84	94.4	24	22 AAB90207	Factor VIIa (FVIIa
28	83	93.3	13	22 AAB90145	Factor VIIa (FVIIa
29	83	93.3	24	22 AAB90171	Factor VIIa (FVIIa
30	83	93.3	24	22 AAB90177	Factor VIIa (FVIIa
31	83	93.3	24	22 AAB90179	Factor VIIa (FVIIa
32	82	92.1	18	22 AAB90219	Factor VIIa (FVIIa
33	82	92.1	20	22 AAB90231	Factor VIIa (FVIIa
34	82	92.1	20	22 AAB90237	Factor VIIa (FVIIa
35	81	91.0	18	22 AAB90220	Factor VIIa (FVIIa
36	80	89.9	24	22 AAB90204	Factor VIIa (FVIIa
37	80	89.9	24	22 AAB90205	Factor VIIa (FVIIa
38	80	89.9	24	22 AAB90206	Factor VIIa (FVIIa
39	79	88.8	22	22 AAB90202	Factor VIIa (FVIIa
40	79	88.8	24	22 AAB90188	Factor VIIa (FVIIa
41	79	88.8	24	22 AAB90191	Factor VIIa (FVIIa
42	79	88.8	24	22 AAB90201	Factor VIIa (FVIIa
43	78	87.6	18	22 AAB90218	Factor VIIa (FVIIa
44	78	87.6	18	22 AAB90221	Factor VIIa (FVIIa
45	78	87.6	20	22 AAB90209	Factor VIIa (FVIIa

ALIGNMENTS

RESULT 1  
AAB90146  
ID AAB90146 standard; Peptide; 13 AA.

XX AAB90146;

AC AAB90146;

DT 23-MAY-2001 (first entry)

XX Factor VIIa (FVIIa) antagonist peptide SEQ ID 4.

XX Antagonist; factor VIIa; FVIIa; blood coagulation factor; inhibitor;  
KW chronic thrombembolic disease; fibrin formation; vascular disorder;  
KW deep vein thrombosis; arterial thrombosis; stroke; metastasis;  
KW thrombolysis; arteriosclerosis; restenosis; inflammation; septic shock;  
KW septicaemia; hypotension; angioedema; ARDS.

OS Synthetic.

XX WO200110892-A2.

XX 15-FEB-2001.

XX 04-AUG-2000; 2000WO-US21296.

XX 06-AUG-1999; 99US-0147627.

XX 23-AUG-1999; 99US-0150315.

XX (GETH ) GENENTECH INC.

XX Dennis MS;

XX WPI; 2001-211069/21.

PT New factor VIIa antagonist peptide for research, diagnostic,  
 PT therapeutic and prophylactic methods, inhibits FVII/FVIIa mediated  
 PT processes and blocks initial events of blood coagulation -  
 XX  
 XX Claim 1; Page 49; 80pp; English.

XX This invention relates to peptides which act as antagonist of Factor VIIa  
 CC (FVIIa). FVIIa is a trypsin-like serine protease blood coagulation  
 CC factor. FVIIa antagonist peptides are useful for inhibiting FVIIa  
 CC activity in the presence of a tissue factor (TF) and for treating a  
 CC TF/FVIIa mediated disease or disorder in a host. Diseases which can be  
 CC treated include chronic thrombembolic diseases or disorders associated  
 CC with fibrin formation including vascular disorders such as deep venous  
 CC thrombosis, arterial thrombosis, stroke, tumour metastasis, thrombolysis,  
 CC arteriosclerosis and restenosis following angioplasty, acute and chronic  
 CC indications such as inflammation, septic shock, septicaemia, hypotension,  
 CC cardiopulmonary bypass surgery, hereditary angioedema, adult respiratory  
 CC distress syndrome (ARDS), disseminated intravascular coagulopathy (DIC)  
 CC and other diseases like inflammatory disorders. The antagonist peptides  
 CC are also useful in research, and for diagnostic, therapeutic and  
 CC prophylactic purposes. The present sequence represents a factor VIIa  
 CC antagonist peptide of the invention.

XX Sequence 13 AA;  
 SQ  
 Query Match 100.0%; Score 89; DB 22; Length 13;  
 Best Local Similarity 100.0%; Pred. No. 4.7e-06;  
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 WEVLCWTWETCER 13  
 DB 1 WEVLCWTWETCER 13

RESULT 2  
 AAB90165  
 ID AAB90165 standard; Peptide; 15 AA.

XX  
 AC AAB90165;  
 XX  
 DT 23-MAY-2001 (first entry)  
 DE Factor VIIa (FVIIa) antagonist peptide SEQ ID 23.

XX Antagonist; factor VIIa; FVIIa; blood coagulation factor; inhibitor;  
 KW chronic thrombembolic disease; fibrin formation; vascular disorder;  
 KW deep vein thrombosis; arterial thrombosis; stroke; metastasis;  
 KW thrombolysis; arteriosclerosis; restenosis; inflammation; septic shock;  
 KW septicaemia; hypotension; angioedema; ARDS.

OS Synthetic.  
 XX  
 PN WO200110892-A2.  
 XX  
 PD 15-FEB-2001.

XX 04-AUG-2000; 2000WO-US21296.  
 PF  
 XX 06-AUG-1999; 99US-0147627.  
 PR  
 XX 23-AUG-1999; 99US-0150315.

XX (GETH ) GENENTECH INC.  
 PA  
 XX Dennis MS;  
 PI  
 XX WPI; 2001-211069/21.

XX New factor VIIa antagonist peptide for research, diagnostic,  
 PT therapeutic and prophylactic methods, inhibits FVII/FVIIa mediated  
 PT processes and blocks initial events of blood coagulation -  
 XX  
 XX Example 1; Fig 4; 80pp; English.

CC This invention relates to peptides which act as antagonist of Factor VIIa  
 CC (FVIIa). FVIIa is a trypsin-like serine protease blood coagulation  
 CC factor. FVIIa antagonist peptides are useful for inhibiting FVIIa  
 CC activity in the presence of a tissue factor (TF) and for treating a  
 CC TF/FVIIa mediated disease or disorder in a host. Diseases which can be  
 CC treated include chronic thrombembolic diseases or disorders associated  
 CC with fibrin formation including vascular disorders such as deep venous  
 CC thrombosis, arterial thrombosis, stroke, tumour metastasis, thrombolysis,  
 CC arteriosclerosis and restenosis following angioplasty, acute and chronic  
 CC indications such as inflammation, septic shock, septicaemia, hypotension,  
 CC cardiopulmonary bypass surgery, hereditary angioedema, adult respiratory  
 CC distress syndrome (ARDS), disseminated intravascular coagulopathy (DIC)  
 CC and other diseases like inflammatory disorders. The antagonist peptides  
 CC are also useful in research, and for diagnostic, therapeutic and  
 CC prophylactic purposes. The present sequence represents a factor VIIa  
 CC antagonist peptide of the invention.

XX Sequence 15 AA;

SQ  
 Query Match 100.0%; Score 89; DB 22; Length 15;  
 Best Local Similarity 100.0%; Pred. No. 5.4e-06;  
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 WEVLCWTWETCER 13  
 DB 3 WEVLCWTWETCER 15

RESULT 3  
 AAB90159  
 ID AAB90159 standard; Peptide; 16 AA.

XX  
 AC AAB90159;  
 XX  
 DT 23-MAY-2001 (first entry)  
 DE Factor VIIa (FVIIa) antagonist peptide SEQ ID 17.

XX Antagonist; factor VIIa; FVIIa; blood coagulation factor; inhibitor;  
 KW chronic thrombembolic disease; fibrin formation; vascular disorder;  
 KW deep vein thrombosis; arterial thrombosis; stroke; metastasis;  
 KW thrombolysis; arteriosclerosis; restenosis; inflammation; septic shock;  
 KW septicaemia; hypotension; angioedema; ARDS.

OS Synthetic.  
 XX  
 PN WO200110892-A2.  
 XX  
 PD 15-FEB-2001.

XX 04-AUG-2000; 2000WO-US21296.  
 PF  
 XX 06-AUG-1999; 99US-0147627.  
 PR  
 XX 23-AUG-1999; 99US-0150315.

XX (GETH ) GENENTECH INC.  
 PA  
 XX Dennis MS;  
 PI  
 XX WPI; 2001-211069/21.

XX New factor VIIa antagonist peptide for research, diagnostic,  
 PT therapeutic and prophylactic methods, inhibits FVII/FVIIa mediated  
 PT processes and blocks initial events of blood coagulation -  
 XX  
 XX Example 1; Fig 4; 80pp; English.

XX This invention relates to peptides which act as antagonist of Factor VIIa  
 CC (FVIIa). FVIIa is a trypsin-like serine protease blood coagulation  
 CC factor. FVIIa antagonist peptides are useful for inhibiting FVIIa  
 CC activity in the presence of a tissue factor (TF) and for treating a  
 CC TF/FVIIa mediated disease or disorder in a host. Diseases which can be  
 CC treated include chronic thrombembolic diseases or disorders associated

CC with fibrin formation including vascular disorders such as deep venous  
 CC thrombosis, arterial thrombosis, stroke, tumour metastasis, thrombolysis,  
 CC arteriosclerosis and restenosis following angioplasty, acute and chronic  
 CC indications such as inflammation, septic shock, septicemia, hypotension,  
 CC cardiopulmonary bypass surgery, hereditary angioedema, adult respiratory  
 CC distress syndrome (ARDS), disseminated intravascular coagulopathy (DIC)  
 CC and other diseases like inflammatory disorders. The antagonist peptides  
 CC are also useful in research, and for diagnostic, therapeutic and  
 CC prophylactic purposes. The present sequence represents a factor VIIa  
 CC antagonist peptide of the invention.

SQ Sequence 16 AA;  
 Query Match 100.0%; Score 89; DB 22; Length 16;  
 Best Local Similarity 100.0%; Pred. No. 5.7e-06;  
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 WEVLCTWTETCER 13  
 | | | | | | | | | | | | | |  
 Db 2 WEVLCTWTETCER 14

RESULT 4  
 AAB90160  
 ID AAB90160 standard; Peptide; 18 AA.  
 XX  
 AC AAB90160;

DT 23-MAY-2001 (first entry)

XX Factor VIIa (FVIIa) antagonist peptide SEQ ID 18.

XX Antagonist; factor VIIa; FVIIa; blood coagulation factor; inhibitor;  
 KW chronic thrombolytic disease; fibrin formation; vascular disorder;  
 KW deep vein thrombosis; arterial thrombosis; stroke; metastasis;  
 KW thrombolysis; arteriosclerosis; restenosis; inflammation; septic shock;  
 KW septicaemia; hypotension; angioedema; ARDS.

XX Synthetic.

XX WO200110892-A2.

XX 15-FEB-2001.

XX 04-AUG-2000; 2000WO-US21296.

XX 06-AUG-1999; 99US-0147627.

XX 23-AUG-1999; 99US-0150315.

XX (GETH ) GENENTECH INC.

XX Dennis MS;

XX WPI; 2001-211069/21.

XX New factor VIIa antagonist peptide for research, diagnostic,  
 PT therapeutic and prophylactic methods, inhibits FVII/FVIIa mediated  
 PT processes and blocks initial events of blood coagulation -

XX Example 1; Fig 4; 80pp; English.

XX This invention relates to peptides which act as antagonist of Factor VIIa  
 CC (FVIIa). FVIIa is a trypsin-like serine protease blood coagulation  
 CC factor. FVIIa antagonist peptides are useful for inhibiting FVIIa  
 CC activity in the presence of a tissue factor (TF) and for treating a  
 CC TF/FVIIa mediated disease or disorder in a host. Diseases which can be  
 CC treated include chronic thrombolytic diseases or disorders associated  
 CC with fibrin formation including vascular disorders such as deep venous  
 CC thrombosis, arterial thrombosis, stroke, tumour metastasis, thrombolysis,  
 CC arteriosclerosis and restenosis following angioplasty, acute and chronic  
 CC indications such as inflammation, septic shock, septicemia, hypotension,  
 CC cardiopulmonary bypass surgery, hereditary angioedema, adult respiratory  
 CC distress syndrome (ARDS), disseminated intravascular coagulopathy (DIC)

CC and other diseases like inflammatory disorders. The antagonist peptides  
 CC are also useful in research, and for diagnostic, therapeutic and  
 CC prophylactic purposes. The present sequence represents a factor VIIa  
 CC antagonist peptide of the invention.

SQ Sequence 18 AA;

Query Match 100.0%; Score 89; DB 22; Length 18;  
 Best Local Similarity 100.0%; Pred. No. 6.4e-06;  
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 WEVLCTWTETCER 13  
 | | | | | | | | | | | | | |  
 Db 3 WEVLCTWTETCER 15

RESULT 5  
 AAB90199  
 ID AAB90199 standard; Peptide; 22 AA.  
 XX  
 AC AAB90199;

DT 23-MAY-2001 (first entry)

XX Factor VIIa (FVIIa) antagonist peptide SEQ ID 57.

XX Antagonist; factor VIIa; FVIIa; blood coagulation factor; inhibitor;  
 KW chronic thrombolytic disease; fibrin formation; vascular disorder;  
 KW deep vein thrombosis; arterial thrombosis; stroke; metastasis;  
 KW thrombolysis; arteriosclerosis; restenosis; inflammation; septic shock;  
 KW septicaemia; hypotension; angioedema; ARDS.

XX Synthetic.

XX WO200110892-A2.

XX 15-FEB-2001.

XX 04-AUG-2000; 2000WO-US21296.

XX 06-AUG-1999; 99US-0147627.

XX 23-AUG-1999; 99US-0150315.

XX (GETH ) GENENTECH INC.

XX Dennis MS;

XX WPI; 2001-211069/21.

XX New factor VIIa antagonist peptide for research, diagnostic,  
 PT therapeutic and prophylactic methods, inhibits FVII/FVIIa mediated  
 PT processes and blocks initial events of blood coagulation -

XX Example 1; Fig 4; 80pp; English.

XX This invention relates to peptides which act as antagonist of Factor VIIa  
 CC (FVIIa). FVIIa is a trypsin-like serine protease blood coagulation  
 CC factor. FVIIa antagonist peptides are useful for inhibiting FVIIa  
 CC activity in the presence of a tissue factor (TF) and for treating a  
 CC TF/FVIIa mediated disease or disorder in a host. Diseases which can be  
 CC treated include chronic thrombolytic diseases or disorders associated  
 CC with fibrin formation including vascular disorders such as deep venous  
 CC thrombosis, arterial thrombosis, stroke, tumour metastasis, thrombolysis,  
 CC arteriosclerosis and restenosis following angioplasty, acute and chronic  
 CC indications such as inflammation, septic shock, septicemia, hypotension,  
 CC cardiopulmonary bypass surgery, hereditary angioedema, adult respiratory  
 CC distress syndrome (ARDS), disseminated intravascular coagulopathy (DIC)  
 CC and other diseases like inflammatory disorders. The antagonist peptides  
 CC are also useful in research, and for diagnostic, therapeutic and  
 CC prophylactic purposes. The present sequence represents a factor VIIa  
 CC antagonist peptide of the invention.

XX Sequence 22 AA;

Query Match 100.0%; Score 89; DB 22; Length 22;  
 Best Local Similarity 100.0%; Pred. No. 7.8e-06;  
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 WEVLCWTWETCER 13  
 ID AAB90161  
 DB 1 WEVLCWTWETCER 13

RESULT 6  
 AAB90161  
 ID AAB90161 standard; Peptide; 24 AA.

AC AAB90161;  
 DT 23-MAY-2001 (first entry)  
 DE Factor VIIa (FVIIa) antagonist peptide SEQ ID 19.

Antagonist; factor VIIa; FVIIa; blood coagulation factor; inhibitor;  
 chronic thrombembolic disease; fibrin formation; vascular disorder;  
 deep vein thrombosis; arterial thrombosis; stroke; metastasis;  
 thrombolysis; arteriosclerosis; restenosis; inflammation; septic shock;  
 septicaemia; hypotension; angioedema; ARDS.

OS Synthetic.  
 XX WO200110892-A2.  
 PN 15-FEB-2001.  
 PD 04-AUG-2000; 2000WO-US21296.  
 PF 06-AUG-1999; 99US-0147627.  
 PR 23-AUG-1999; 99US-0150315.

PA (GETH ) GENENTECH INC.  
 PI Dennis MS;  
 XX WPI; 2001-211069/21.

PT New factor VIIa antagonist peptide for research, diagnostic,  
 therapeutic and prophylactic methods, inhibits FVII/FVIIa mediated  
 processes and blocks initial events of blood coagulation -  
 XX Example 1; Fig 4; 80pp; English.

XX This invention relates to peptides which act as antagonist of Factor VIIa  
 (FVIIa). FVIIa is a trypsin-like serine protease blood coagulation  
 factor. FVIIa antagonist peptides are useful for inhibiting FVIIa  
 activity in the presence of a tissue factor (TF) and for treating a  
 TF/FVIIa mediated disease or disorder in a host. Diseases which can be  
 treated include chronic thrombembolic diseases or disorders associated  
 with fibrin formation including vascular disorders such as deep venous  
 thrombosis, arterial thrombosis, stroke, tumour metastasis, thrombolysis,  
 arteriosclerosis and restenosis following angioplasty, acute and chronic  
 indications such as inflammation, septic shock, septicaemia, hypotension,  
 cardiopulmonary bypass surgery, hereditary angioedema, adult respiratory  
 distress syndrome (ARDS), disseminated intravascular coagulopathy (DIC)  
 and other diseases like inflammatory disorders. The antagonist peptides  
 are also useful in research, and for diagnostic, therapeutic and  
 prophylactic purposes. The present sequence represents a factor VIIa  
 antagonist peptide of the invention.

QY Sequence 24 AA;  
 Query Match 100.0%; Score 89; DB 22; Length 24;  
 Best Local Similarity 100.0%; Pred. No. 8.5e-06;  
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 WEVLCWTWETCER 13

DB 3 WEVLCWTWETCER 15  
 ID AAB90168 standard; Peptide; 24 AA.

AC AAB90168;  
 DT 23-MAY-2001 (first entry)  
 DE Factor VIIa (FVIIa) antagonist peptide SEQ ID 26.

Antagonist; factor VIIa; FVIIa; blood coagulation factor; inhibitor;  
 chronic thrombembolic disease; fibrin formation; vascular disorder;  
 deep vein thrombosis; arterial thrombosis; stroke; metastasis;  
 thrombolysis; arteriosclerosis; restenosis; inflammation; septic shock;  
 septicaemia; hypotension; angioedema; ARDS.

OS Synthetic.  
 XX WO200110892-A2.

PN 15-FEB-2001.  
 PD 04-AUG-2000; 2000WO-US21296.  
 PF 06-AUG-1999; 99US-0147627.  
 PR 23-AUG-1999; 99US-0150315.

PA (GETH ) GENENTECH INC.  
 PI Dennis MS;  
 XX WPI; 2001-211069/21.

PT New factor VIIa antagonist peptide for research, diagnostic,  
 therapeutic and prophylactic methods, inhibits FVII/FVIIa mediated  
 processes and blocks initial events of blood coagulation -  
 XX Example 1; Fig 4; 80pp; English.

XX This invention relates to peptides which act as antagonist of Factor VIIa  
 (FVIIa). FVIIa is a trypsin-like serine protease blood coagulation  
 factor. FVIIa antagonist peptides are useful for inhibiting FVIIa  
 activity in the presence of a tissue factor (TF) and for treating a  
 TF/FVIIa mediated disease or disorder in a host. Diseases which can be  
 treated include chronic thrombembolic diseases or disorders associated  
 with fibrin formation including vascular disorders such as deep venous  
 thrombosis, arterial thrombosis, stroke, tumour metastasis, thrombolysis,  
 arteriosclerosis and restenosis following angioplasty, acute and chronic  
 indications such as inflammation, septic shock, septicaemia, hypotension,  
 cardiopulmonary bypass surgery, hereditary angioedema, adult respiratory  
 distress syndrome (ARDS), disseminated intravascular coagulopathy (DIC)  
 and other diseases like inflammatory disorders. The antagonist peptides  
 are also useful in research, and for diagnostic, therapeutic and  
 prophylactic purposes. The present sequence represents a factor VIIa  
 antagonist peptide of the invention.

QY Sequence 24 AA;  
 Query Match 100.0%; Score 89; DB 22; Length 24;  
 Best Local Similarity 100.0%; Pred. No. 8.5e-06;  
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 WEVLCWTWETCER 13  
 ID AAB90169

ID XX AAB90169 standard; Peptide; 24 AA.  
 AC AAB90169;  
 XX  
 DT 23-MAY-2001 (first entry)  
 XX  
 DE Factor VIIa (FVIIa) antagonist peptide SEQ ID 27.  
 XX  
 KW Antagonist; factor VIIa; FVIIa; blood coagulation factor; inhibitor;  
 KW chronic thrombembolic disease; fibrin formation; vascular disorder;  
 KW deep vein thrombosis; arterial thrombosis; stroke; metastasis;  
 KW thrombolysis; arteriosclerosis; restenosis; inflammation; septic shock;  
 KW septicaemia; hypotension; angioedema; ARDS.  
 XX  
 OS Synthetic.  
 XX  
 PN WO200110892-A2.  
 XX  
 PD 15-FEB-2001.  
 XX  
 PF 04-AUG-2000; 2000WO-US21296.  
 XX  
 PR 06-AUG-1999; 99US-0147627.  
 PR 23-AUG-1999; 99US-0150315.  
 XX  
 PA (GETH ) GENENTECH INC.  
 XX  
 PI Dennis MS;  
 XX  
 DR WPI; 2001-211069/21.  
 XX  
 XX New factor VIIa antagonist peptide for research, diagnostic,  
 PT therapeutic and prophylactic methods, inhibits FVII/FVIIa mediated  
 PT processes and blocks initial events of blood coagulation -  
 XX  
 PS Example 1; Fig 4; 80pp; English.  
 XX  
 CC This invention relates to peptides which act as antagonist of Factor VIIa  
 CC (FVIIa). FVIIa is a trypsin-like serine protease blood coagulation  
 CC factor. FVIIa antagonist peptides are useful for inhibiting FVIIa  
 CC activity in the presence of a tissue factor (TF) and for treating a  
 CC TF/FVIIa mediated disease or disorder in a host. Diseases which can be  
 CC treated include chronic thrombembolic diseases or disorders associated  
 CC with fibrin formation including vascular disorders such as deep venous  
 CC thrombosis, arterial thrombosis, stroke, tumour metastasis, thrombolysis,  
 CC arteriosclerosis and restenosis following angioplasty, acute and chronic  
 CC indications such as inflammation, septic shock, septicaemia, hypotension,  
 CC cardiopulmonary bypass surgery, hereditary angioedema, adult respiratory  
 CC distress syndrome (ARDS), disseminated intravascular coagulopathy (DIC)  
 CC and other diseases like inflammatory disorders. The antagonist peptides  
 CC are also useful in research, and for diagnostic, therapeutic and  
 CC prophylactic purposes. The present sequence represents a factor VIIa  
 CC antagonist peptide of the invention.  
 XX  
 SQ Sequence 24 AA;  
 Query Match 100.0%; Score 89; DB 22; Length 24;  
 Best Local Similarity 100.0%; Pred. No. 8.5e-06;  
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 WEVLCWTWETCER 13  
 Db 3 WEVLCWTWETCER 15  
 RESULT 9  
 AAB90181  
 ID AAB90181 standard; Peptide; 24 AA.  
 XX  
 AC AAB90181;  
 XX  
 DT 23-MAY-2001 (first entry)  
 XX

DE Factor VIIa (FVIIa) antagonist peptide SEQ ID 39.  
 XX  
 KW Antagonist; factor VIIa; FVIIa; blood coagulation factor; inhibitor;  
 KW chronic thrombembolic disease; fibrin formation; vascular disorder;  
 KW deep vein thrombosis; arterial thrombosis; stroke; metastasis;  
 KW thrombolysis; arteriosclerosis; restenosis; inflammation; septic shock;  
 KW septicaemia; hypotension; angioedema; ARDS.  
 XX  
 OS Synthetic.  
 XX  
 PN WO200110892-A2.  
 XX  
 PD 15-FEB-2001.  
 XX  
 PF 04-AUG-2000; 2000WO-US21296.  
 XX  
 PR 06-AUG-1999; 99US-0147627.  
 PR 23-AUG-1999; 99US-0150315.  
 XX  
 PA (GETH ) GENENTECH INC.  
 XX  
 PI Dennis MS;  
 XX  
 DR WPI; 2001-211069/21.  
 XX  
 XX New factor VIIa antagonist peptide for research, diagnostic,  
 PT therapeutic and prophylactic methods, inhibits FVII/FVIIa mediated  
 PT processes and blocks initial events of blood coagulation -  
 XX  
 PS Example 1; Fig 4; 80pp; English.  
 XX  
 CC This invention relates to peptides which act as antagonist of Factor VIIa  
 CC (FVIIa). FVIIa is a trypsin-like serine protease blood coagulation  
 CC factor. FVIIa antagonist peptides are useful for inhibiting FVIIa  
 CC activity in the presence of a tissue factor (TF) and for treating a  
 CC TF/FVIIa mediated disease or disorder in a host. Diseases which can be  
 CC treated include chronic thrombembolic diseases or disorders associated  
 CC with fibrin formation including vascular disorders such as deep venous  
 CC thrombosis, arterial thrombosis, stroke, tumour metastasis, thrombolysis,  
 CC arteriosclerosis and restenosis following angioplasty, acute and chronic  
 CC indications such as inflammation, septic shock, septicaemia, hypotension,  
 CC cardiopulmonary bypass surgery, hereditary angioedema, adult respiratory  
 CC distress syndrome (ARDS), disseminated intravascular coagulopathy (DIC)  
 CC and other diseases like inflammatory disorders. The antagonist peptides  
 CC are also useful in research, and for diagnostic, therapeutic and  
 CC prophylactic purposes. The present sequence represents a factor VIIa  
 CC antagonist peptide of the invention.  
 XX  
 SQ Sequence 24 AA;  
 Query Match 100.0%; Score 89; DB 22; Length 24;  
 Best Local Similarity 100.0%; Pred. No. 8.5e-06;  
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 WEVLCWTWETCER 13  
 Db 3 WEVLCWTWETCER 15  
 RESULT 10  
 AAB90182  
 ID AAB90182 standard; Peptide; 24 AA.  
 XX  
 AC AAB90182;  
 XX  
 DT 23-MAY-2001 (first entry)  
 XX  
 DE Factor VIIa (FVIIa) antagonist peptide SEQ ID 40.  
 XX  
 KW Antagonist; factor VIIa; FVIIa; blood coagulation factor; inhibitor;  
 KW chronic thrombembolic disease; fibrin formation; vascular disorder;  
 KW deep vein thrombosis; arterial thrombosis; stroke; metastasis;  
 KW thrombolysis; arteriosclerosis; restenosis; inflammation; septic shock;



XX PA (GETH ) GENENTECH INC.  
 XX PT Dennis MS;  
 XX PI  
 XX PS WPI; 2001-211069/21.  
 XX DR  
 XX XX  
 PT New factor VIIa antagonist peptide for research, diagnostic,  
 PT therapeutic and prophylactic methods, inhibits FVII/FVIIa mediated  
 PT processes and blocks initial events of blood coagulation -  
 XX XX  
 XX PS Example 1; Fig 4; 80pp; English.  
 XX DR  
 XX XX  
 CC This invention relates to peptides which act as antagonist of Factor VIIa  
 CC (FVIIa). FVIIa is a trypsin-like serine protease blood coagulation  
 CC factor. FVIIa antagonist peptides are useful for inhibiting FVIIa  
 CC activity in the presence of a tissue factor (TF) and for treating a  
 CC TF/FVIIa mediated disease or disorder in a host. Diseases which can be  
 CC treated include chronic thrombembolic diseases or disorders associated  
 CC with fibrin formation including vascular disorders such as deep venous  
 CC thrombosis, arterial thrombosis, stroke, tumour metastasis, thrombolysis,  
 CC arteriosclerosis and restenosis following angioplasty, acute and chronic  
 CC indications such as inflammation, septic shock, septicaemia, hypotension,  
 CC cardiopulmonary bypass surgery, hereditary angioedema, adult respiratory  
 CC distress syndrome (ARDS), disseminated intravascular coagulopathy (DIC)  
 CC and other diseases like inflammatory disorders. The antagonist peptides  
 CC are also useful in research, and for diagnostic, therapeutic and  
 CC prophylactic purposes. The present sequence represents a factor VIIa  
 CC antagonist peptide of the invention.  
 XX SQ Sequence 24 AA;  
 Query Match 98.9%; Score 88; DB 22; Length 24;  
 Best Local Similarity 92.3%; Pred. No. 1.2e-05;  
 Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 WEVLCWTWETCER 13  
 Db ||:|||||||||  
 3 WEVLCWTWETCER 15  
 RESULT 13  
 AAB90185  
 ID AAB90185 standard; Peptide; 24 AA.  
 XX AC  
 XX AAB90185;  
 XX XX  
 DT 23-MAY-2001 (first entry)  
 XX XX  
 DE Factor VIIa (FVIIa) antagonist peptide SEQ ID 43.  
 XX KW Antagonist; factor VIIa; FVIIa; blood coagulation factor; inhibitor;  
 KW chronic thrombembolic disease; fibrin formation; vascular disorder;  
 KW deep vein thrombosis; arterial thrombosis; stroke; metastasis;  
 KW thrombolysis; arteriosclerosis; restenosis; inflammation; septic shock;  
 KW septicaemia; hypotension; angioedema; ARDS.  
 XX OS Synthetic.  
 XX XX  
 PN WO200110892-A2.  
 XX XX  
 PD 15-FEB-2001.  
 XX XX  
 PF 04-AUG-2000; 2000WO-US21296.  
 XX XX  
 PR 06-AUG-1999; 99US-0147627.  
 PR 23-AUG-1999; 99US-0150315.  
 XX XX  
 PA (GETH ) GENENTECH INC.  
 XX PT Dennis MS;  
 XX PI  
 XX PS WPI; 2001-211069/21.  
 XX DR

XX PT New factor VIIa antagonist peptide for research, diagnostic,  
 PT therapeutic and prophylactic methods, inhibits FVII/FVIIa mediated  
 PT processes and blocks initial events of blood coagulation -  
 XX XX  
 XX PS Example 1; Fig 4; 80pp; English.  
 XX DR  
 XX XX  
 CC This invention relates to peptides which act as antagonist of Factor VIIa  
 CC (FVIIa). FVIIa is a trypsin-like serine protease blood coagulation  
 CC factor. FVIIa antagonist peptides are useful for inhibiting FVIIa  
 CC activity in the presence of a tissue factor (TF) and for treating a  
 CC TF/FVIIa mediated disease or disorder in a host. Diseases which can be  
 CC treated include chronic thrombembolic diseases or disorders associated  
 CC with fibrin formation including vascular disorders such as deep venous  
 CC thrombosis, arterial thrombosis, stroke, tumour metastasis, thrombolysis,  
 CC arteriosclerosis and restenosis following angioplasty, acute and chronic  
 CC indications such as inflammation, septic shock, septicaemia, hypotension,  
 CC cardiopulmonary bypass surgery, hereditary angioedema, adult respiratory  
 CC distress syndrome (ARDS), disseminated intravascular coagulopathy (DIC)  
 CC and other diseases like inflammatory disorders. The antagonist peptides  
 CC are also useful in research, and for diagnostic, therapeutic and  
 CC prophylactic purposes. The present sequence represents a factor VIIa  
 CC antagonist peptide of the invention.  
 XX SQ Sequence 24 AA;  
 Query Match 97.8%; Score 87; DB 22; Length 24;  
 Best Local Similarity 92.3%; Pred. No. 1.6e-05;  
 Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 WEVLCWTWETCER 13  
 Db |||:|||||||||  
 3 WEVLCWTWETCER 15  
 RESULT 14  
 AAB90186  
 ID AAB90186 standard; Peptide; 24 AA.  
 XX AC  
 XX AAB90186;  
 XX XX  
 DT 23-MAY-2001 (first entry)  
 XX XX  
 DE Factor VIIa (FVIIa) antagonist peptide SEQ ID 44.  
 XX KW Antagonist; factor VIIa; FVIIa; blood coagulation factor; inhibitor;  
 KW chronic thrombembolic disease; fibrin formation; vascular disorder;  
 KW deep vein thrombosis; arterial thrombosis; stroke; metastasis;  
 KW thrombolysis; arteriosclerosis; restenosis; inflammation; septic shock;  
 KW septicaemia; hypotension; angioedema; ARDS.  
 XX OS Synthetic.  
 XX XX  
 PN WO200110892-A2.  
 XX XX  
 PD 15-FEB-2001.  
 XX XX  
 PF 04-AUG-2000; 2000WO-US21296.  
 XX XX  
 PR 06-AUG-1999; 99US-0147627.  
 PR 23-AUG-1999; 99US-0150315.  
 XX XX  
 PA (GETH ) GENENTECH INC.  
 XX PT Dennis MS;  
 XX PI  
 XX PS WPI; 2001-211069/21.  
 XX DR  
 XX XX  
 PT New factor VIIa antagonist peptide for research, diagnostic,  
 PT therapeutic and prophylactic methods, inhibits FVII/FVIIa mediated  
 PT processes and blocks initial events of blood coagulation -  
 XX XX  
 XX PS Example 1; Fig 4; 80pp; English.

XX This invention relates to peptides which act as antagonist of Factor VIIa  
 CC (FVIIa). FVIIa is a trypsin-like serine protease blood coagulation  
 CC factor. FVIIa antagonist peptides are useful for inhibiting FVIIa  
 CC activity in the presence of a tissue factor (TF) and for treating a  
 CC TF/FVIIa mediated disease or disorder in a host. Diseases which can be  
 CC treated include chronic thrombembolic diseases or disorders associated  
 CC with fibrin formation including vascular disorders such as deep venous  
 CC thrombosis, arterial thrombosis, stroke, tumour metastasis, thrombolysis,  
 CC arteriosclerosis and restenosis following angioplasty, acute and chronic  
 CC indications such as inflammation, septic shock, septicaemia, hypotension,  
 CC cardiopulmonary bypass surgery, hereditary angioedema, adult respiratory  
 CC distress syndrome (ARDS), disseminated intravascular coagulopathy (DIC)  
 CC and other diseases like inflammatory disorders. The antagonist peptides  
 CC are also useful in research, and for diagnostic, therapeutic and  
 CC prophylactic purposes. The present sequence represents a factor VIIa  
 CC antagonist peptide of the invention.

XX Sequence 24 AA;

Query Match 97.8%; Score 87; DB 22; Length 24;  
 Best Local Similarity 92.3%; Pred. No. 1.6e-05;  
 Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 WEVLCWTWETCER 13  
 |||:|||||  
 Db 3 WEVVCWTWETCER 15

# RESULT 15

AAB90147  
 ID AAB90147 standard; Peptide; 13 AA.

XX AAB90147;

XX 23-MAY-2001 (first entry)

XX Factor VIIa (FVIIa) antagonist peptide SEQ ID 5.

XX Antagonist; factor VIIa; FVIIa; blood coagulation factor; inhibitor;  
 KW chronic thrombembolic disease; fibrin formation; vascular disorder;  
 KW deep vein thrombosis; arterial thrombosis; stroke; metastasis;  
 KW thrombolysis; arteriosclerosis; restenosis; inflammation; septic shock;  
 KW septicaemia; hypotension; angioedema; ARDS.

XX Synthetic.

XX WO200110892-A2.

XX 15-FEB-2001.

XX 04-AUG-2000; 2000WO-US21296.

XX 06-AUG-1999; 99US-0147627.

XX 23-AUG-1999; 99US-0150315.

XX (GETH ) GENENTECH INC.

XX Dennis MS;

XX WPI; 2001-211069/21.

XX New factor VIIa antagonist peptide for research, diagnostic,  
 PT therapeutic and prophylactic methods, inhibits FVII/FVIIa mediated  
 PT processes and blocks initial events of blood coagulation -

XX Example 1; Fig 4; 80pp; English.

XX This invention relates to peptides which act as antagonist of Factor VIIa  
 CC (FVIIa). FVIIa is a trypsin-like serine protease blood coagulation  
 CC factor. FVIIa antagonist peptides are useful for inhibiting FVIIa  
 CC activity in the presence of a tissue factor (TF) and for treating a  
 CC TF/FVIIa mediated disease or disorder in a host. Diseases which can be

CC treated include chronic thrombembolic diseases or disorders associated  
 CC with fibrin formation including vascular disorders such as deep venous  
 CC thrombosis, arterial thrombosis, stroke, tumour metastasis, thrombolysis,  
 CC arteriosclerosis and restenosis following angioplasty, acute and chronic  
 CC indications such as inflammation, septic shock, septicaemia, hypotension,  
 CC cardiopulmonary bypass surgery, hereditary angioedema, adult respiratory  
 CC distress syndrome (ARDS), disseminated intravascular coagulopathy (DIC)  
 CC and other diseases like inflammatory disorders. The antagonist peptides  
 CC are also useful in research, and for diagnostic, therapeutic and  
 CC prophylactic purposes. The present sequence represents a factor VIIa  
 CC antagonist peptide of the invention.

XX Sequence 13 AA;

Query Match 96.6%; Score 86; DB 22; Length 13;  
 Best Local Similarity 92.3%; Pred. No. 1.2e-05;  
 Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 WEVLCWTWETCER 13

|||:|||||  
 Db 1 WEVVCWTWETCER 13

Search completed: January 9, 2003, 12:24:24  
 Job time : 35 secs